$16.820
-0.266 (-1.58%)收盤時
OBX 同業比較
In the context of the broader market, OBX competes directly with industry leaders such as ABUS and LXRX. With a market capitalization of $1.08B, it holds a leading position in the sector. When comparing efficiency, OBX's gross margin of N/A stands against ABUS's 100.00% and LXRX's 94.36%. Such benchmarking helps identify whether Obsidian Therapeutics, Inc is trading at a premium or discount relative to its financial performance.
OBX 財務表現
The company has a negative price-to-earnings ratio of -12.68 and a forward price-to-earnings ratio of 0, indicating no expected earnings growth in the near term. The price-to-sales ratio is also 0, suggesting no revenue generation at this time.
Financials
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。